Barry S. Skikne

Hematology

2650 Shawnee Mission Pkwy
Westwood, KS 66205

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World Experience.

Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World Experience.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 25, 2025

The Impact of Sponsors on Development of Clinical Research in Multiple Myeloma and AL Amyloidosis: An In-Depth Analysis.

The Impact of Sponsors on Development of Clinical Research in Multiple Myeloma and AL Amyloidosis: An In-Depth Analysis.

Journal: Clinical lymphoma, myeloma & leukemia

Published: March 07, 2025

Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.

Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.

Journal: Cancer medicine

Published: February 29, 2024

Population Pharmacokinetics of Oral Azacitidine, and Exposure-Response Analysis in Acute Myeloid Leukemia.

Population Pharmacokinetics of Oral Azacitidine, and Exposure-Response Analysis in Acute Myeloid Leukemia.

Journal: Clinical pharmacology and therapeutics

Published: February 09, 2023

Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.

Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.

Journal: American journal of hematology

Published: October 31, 2022

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial.

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial.

Journal: Haematologica

Published: October 25, 2022

Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.

Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.

Journal: British journal of haematology

Published: October 16, 2022

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.

Journal: Blood

Published: March 17, 2022

Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.

Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.

Journal: Blood

Published: July 19, 2021

Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.

Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 06, 2021

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.

Journal: Journal of hematology & oncology

Published: May 27, 2021

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.

Journal: Haematologica

Published: May 07, 2021

Showing 1-12 of 34

Last Updated: 09/26/2026